merged_eli-lilly-zepbound-price.txt

<other>Analyzing the article to answer each question based solely on the provided text.</other>
<question_number>1</question_number>
<answer>Positioning vials as a safer option than compounded drugs with less oversight</answer>
<question_number>2</question_number>
<answer>LillyDirect connects patients with providers and delivers vials directly to doors like telehealth companies</answer>
<question_number>3</question_number>
<answer>Compounded drugs subject to far less oversight than approved medications</answer>
<question_number>4</question_number>
<answer>Regaining customers from compounders outweighs potential loss from pen users switching to vials</answer>
<question_number>5</question_number>
<answer>Compounding pharmacies can legally make copycat versions while medication is on FDA shortage list</answer>
<question_number>6</question_number>
<answer>N/A</answer>
<question_number>7</question_number>
<answer>N/A</answer>
<question_number>8</question_number>
<answer>Offering FDA-approved alternative to compounded versions with safety concerns</answer>
<question_number>9</question_number>
<answer>FDA lists tirzepatide as "in shortage"</answer>
<question_number>10</question_number>
<answer>Offering lower pricing to regain market share from compounders</answer>
<other>All questions answered based solely on article content.</other>